FDA approves Cipla’s generic Reyataz
Cipla has received the Food and Drug Administration’s approval for atazanavir capsules, a generic version of Bristol-Myers Squibb Pharma’s Reyataz.
Cipla’s atazanavir caps are available in 100-, 150-, 200- and 300-mg dosage strengths. The product is a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients with minimum age of 6 years and older weighing at least 15 kg.
The product had a market value of approximately $324 million for the 12-month period ending April 2018, according to IQVIA data.
Cipla’s atazanavir caps are available in 100-, 150-, 200- and 300-mg dosage strengths. The product is a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients with minimum age of 6 years and older weighing at least 15 kg.
The product had a market value of approximately $324 million for the 12-month period ending April 2018, according to IQVIA data.